A PYMNTS Company

Spain’s Antitrust Watchdog Fines Drugmaker For ‘Excessive’ Pricing

By  |  November 15, 2022

Antitrust regulators in Spain have fined a drugmaker $10.6 million for years of “excessive” price hikes on a rare disease medicine, the latest instance in which European authorities have cracked down on the pharmaceutical industry for harming consumers and taxpayers.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The National Commission for Markets and Competition, or CNMC, said the company had abused its dominant position as the only supplier in Spain of the only medication available in the country to treat Cerebrotendinous Xanthomatosis (CTX), a rare genetic disease.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Related: Spanish Competition Watchdog Fines Drugmaker Leadiant

    There are fewer than 50 people in Spain who suffer from the disease and who must take the medication for life, according to the watchdog.

    Leadiant had the exclusive rights to sell the active ingredient on which the drug is based and was charging Spain’s national health system 14 times the price of an “essentially identical” treatment it sold in the country until 2010, it added.

    In addition to slapping Leadiant with the fine, the watchdog also ordered it to market the drug in Spain “at a non-excessive price” that will be negotiated with the health ministry.